外周动脉疾病(PAD)与心血管疾病(CV)的发病率和死亡率有着密切的联系。ACCF/AHA指南建议无症状和症状性PAD患者戒烟并应用抗血小板/抗凝药物。对于存在严重肢体缺血(CLI)的PAD患者应考虑接受腔内与开放保肢手术治疗。即便存在CLI的PAD患者接受如上治疗,有时仍无法为患肢提供足够的血流灌注以消除症状。为建立有效血供,许多研究已经深入细胞治疗层面。内皮干细胞、单核细胞和骨髓间充质干细胞在临床应用中得到了很好的研究。血管内皮生长因子、成纤维细胞生长因子和肝细胞生长因子(HGF)也被应用于PAD患者,以诱导血管生成。其中,HGF最有优势,因为它可诱导血管生成却不伴有反应性血管炎及血管通透性增高。同时,血管腔内治疗器械及技术,如药物涂层球囊等也获得较快发展。本文将PAD治疗进展综述如下。 Peripheral arterial disease (PAD) and cardiovascular disease (CV) morbidity and mortality are closely linked. The ACCF / AHA guidelines recommend that asymptomatic and symptomatic PAD patients stop smoking and apply antiplatelet / anticoagulant drugs. PAD patients with severe limb ischemia (CLI) should be considered for endovascular and open limb salvage surgery. Even in patients with PAD in the CLI who receive the above treatment, sometimes it is not possible to provide adequate blood perfusion to the affected limb to eliminate the symptoms. In order to establish an effective blood supply, many researches have gone deep into the cell therapy. Endothelial stem cells, monocytes and bone marrow mesenchymal stem cells have been well studied in clinical practice. Vascular endothelial growth factor, fibroblast growth factor and hepatocyte growth factor (HGF) are also being used in PAD patients to induce angiogenesis. Among them, HGF has the most advantages, because it can induce angiogenesis but not associated with reactive vasculitis and increased vascular permeability. At the same time, intravascular vascular devices and techniques, such as drug-coated balloons, have also gained rapid development. This article reviews the progress of PAD treatment is as follows.